Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Breast Cancer Clinical Trials in New York | 332 Studies

Clinical Trials Breast CancerNew York

Breast Cancer Clinical Trials in New York

Find 332 clinical trials for breast cancer near New York, New York. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in New York

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 161-180 of 332 trials

CompletedA Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerThis multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in…NCT01566721·Tirana and 436 others

Breast Cancer Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

RecruitingA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerThe purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib +…NCT07100106·Huntsville, Alabama and 73 others

TerminatedTesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCCONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).NCT03952325·Fort Myers, Florida and 11 others

TerminatedCelecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal CancerRATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells.NCT00305643·Santa Rosa, California and 13 others

Active not recruitingProspective Randomized Study of Accelerated Radiation Therapy (PRART)Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a…NCT04175210·New York, New York and 2 others

Active not recruitingA Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerThis study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called…NCT03975647·Mobile, Alabama and 489 others

CompletedToll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin MetastasesThis study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and…NCT01421017·New York, New York

RecruitingA Study of a Side Effects and Resource Navigation Program for People With CancerThe purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care.NCT07646847·Basking Ridge, New Jersey and 7 others

CompletedStudy of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerThe primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with…NCT03901339·Avondale, Arizona and 112 others

TerminatedTesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCCONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2 negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not…NCT03858972·Whittier, California and 24 others

RecruitingSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsThis is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion.NCT05732831·Palo Alto, California and 25 others

CompletedA Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsThis research study is done to test how well different types of cancer respond to the drug called larotrectinib.NCT02576431·Palo Alto, California and 97 others

Active not recruitingTesting Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerThis Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive…NCT05705401·Phoenix, Arizona and 417 others

CompletedCharacterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy IndexUtilizing CellSearch® technology, the ability to both enumerate and reliably and reproducibly characterize circulating tumor cells (CTC) for tumor markers that predict endocrine…NCT01701050·Phoenix, Arizona and 19 others

RecruitingSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of…NCT06393374·Mobile, Alabama and 313 others

Active not recruitingA Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerPalbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors…NCT06495164·New York, New York

TerminatedAspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyThis randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2…NCT02927249·Birmingham, Alabama and 1451 others

CompletedZoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast CancerRATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer.NCT00022087·Arroyo Grande, California and 106 others

CompletedStudy to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCThe purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2-…NCT02941926·Anchorage, Alaska and 494 others

CompletedA Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast CancerThe purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast…NCT01268150·Miami, Florida and 16 others

PreviousPage 9 of 17Next

Other Conditions in New York

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma